RxDoctor Payments Data

Charles Wicks, MD

Cardiovascular Disease · Concord, NHNPI 1215092440

Payments from drug & device makers

What this record shows

Abbott accounts for 88.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $1,120, more than ten times the $102 reported in 2019.

$1,682in general payments, 2019–2025

Across 31 payments — averaging $54.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$102
  • Edwards Lifesciences$49
  • Boston Scientific$36
  • Johnson & Johnson$12

What the payments were for

  • Travel & lodging$94956%
  • Food & beverage$73344%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott26$1,484
Abiomed1$102
Edwards Lifesciences1$49
Boston Scientific2$36
Johnson & Johnson1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,682 in reported general payments places this provider in the 65th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$101,757
Medicare patients
1,148
Services billed
1,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$167,362
CamzyosMavacamten14$109,059
XareltoRivaroxaban41$47,171
EntrestoSacubitril/Valsartan34$43,246
JardianceEmpagliflozin32$33,274
Metoprolol Succinate157$1,914
Atorvastatin Calcium156$1,231
Dofetilide11$1,200
Flecainide Acetate21$1,019
ClopidogrelClopidogrel Bisulfate102$855
Amiodarone Hcl32$777
Potassium Chloride18$674
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$672
Ezetimibe33$610
Warfarin Sodium27$504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$12$47,17141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →